Related by context. All words. (Click for frequent words.) 70 LUX Lung 70 HCV SPRINT 68 Initiated Phase 68 Initiate Phase 67 Commences Phase 67 Pivotal Phase 67 Randomized Phase 67 Randomized Phase II 66 treatment naive genotype 66 ExTRACT TIMI 66 multicenter phase 65 Multicenter Phase 65 Commence Phase 65 Phase Ib II 65 fidaxomicin Phase 65 treatment naïve genotype 65 Initiates Phase II 65 randomized controlled Phase 65 RECORD1 64 EXPLORE Xa 64 registrational Phase 64 Second Pivotal Phase 64 Initiates Phase 64 NSABP B 64 Successfully Completes Phase 64 Completes Patient Enrollment 63 Randomized phase 63 placebo controlled Phase 63 Randomized Phase III 63 novel VDA molecule 63 EURIDIS 63 initiated confirmatory Phase 63 Presents Positive 63 REVIVE TA 63 Topline Results 63 multicenter Phase III 63 Clinical Antipsychotic Trials 62 PRE SURGE 62 BRIM3 62 ABCSG 62 ENESTnd 62 evaluating bafetinib 62 Val HeFT 62 phase IIIb 62 Pivotal Phase III 62 Intervention Effectiveness 62 Testosterone MDTS ® 62 Initiates Phase III 62 Presents Positive Preclinical 62 Phase III Pivotal 62 BENCHMRK 62 Omacetaxine 62 NO# [002] 62 TG MV 62 controlled multicenter Phase 61 initiated Phase Ib 61 dose escalation clinical 61 pharmacogenomic translational research 61 multicenter Phase II 61 Phase III HEAT 61 Clin Oncol 61 Completes Enrollment 61 Myocardial Infarction Study 61 Preclinical Models 61 number NCT# ClinicalTrials.gov 61 Meets Primary Endpoint 61 Randomized Double blind 61 ACCLAIM COPD 61 Phase Ib IIa 61 multicenter randomized controlled 61 CALGB # [002] 61 MKC# MT 61 Phase 2b Clinical Trial 61 placebo controlled multicenter 61 rALLy clinical trial 61 Left Ventricular Dysfunction 61 By JENNIFER LEARN 61 Testosterone MDTS R 61 adecatumumab MT# 61 evaluating mipomersen 61 evaluating tesamorelin 61 initiate multicenter 61 FOLOTYN ® 61 Phase IIA 61 Phase III ADT 61 Oral Fingolimod 60 blinded randomized placebo controlled 60 TAXUS ATLAS 60 IIa clinical 60 Dose Ranging 60 GOUT 60 multicentre randomized double 60 RE SURGE 60 randomized controlled multicenter 60 bevirimat Study 60 MEND CABG 60 Trial Evaluating 60 HCV RESPOND 2 60 TASKi2 60 Randomized Double Blind 60 recombinant PSMA vaccine 60 ALSYMPCA 60 Phase Ib clinical 60 STRIDE PD 60 Combination REOLYSIN R 60 CHAMPION PCI 60 Bayer HealthCare Onyx Pharmaceuticals 60 AIR2 Trial 60 IMPACT IMmunotherapy 60 Nephrol Dial Transplant 60 Prospective Randomized 60 Luramist TM 60 phase III ACCLAIM 60 EOquin TM phase 60 Randomised 60 Randomized Evaluation 60 NEVO RES 60 Initiates Enrollment 60 Multicenter Randomized 60 Patient Enrollment 60 CCR5 mAb 60 multicenter randomized Phase 60 Pooled Analysis 60 Arch Neurol 60 Initiates Clinical 60 J Clin 60 Phase III ThermoDox 60 CTAP# Capsules 59 Study Evaluating 59 ENDEAVOR II 59 Randomized Controlled 59 multicentre randomized 59 Phase IIb III 59 lead Aganocide compound 59 Oral Insulin Capsule 59 Phase III multicenter 59 Initiates Clinical Trial 59 Phase III AFFIRM 59 EQUATE OB 59 Systemic Sclerosis 59 Phase 2b Trial 59 unique alkylating agent 59 evaluating tivozanib 59 PRTX 59 Diabetic Macular Edema 59 mg q#h 59 Chronic Hepatitis C 59 Carotid Revascularization Endarterectomy vs. 59 2 inhibitor CYT# 59 nausea dehydration dyspnea 59 BiovaxID Phase 59 MIVI III 59 Randomized controlled 59 multicenter randomized double 59 Clinical Trial Results 59 ABSORB clinical 59 Controlled Trial 59 phase Ib 59 pralatrexate injection folate analogue 59 REVIVE Diabetes 59 tolerability pharmacokinetics 59 J Clin Oncol 59 Prostate AdenoCarcinoma Treatment 59 ENDEAVOR IV 59 ZYBRESTAT fosbretabulin 59 relapsed MM 59 First Patient Enrolled 59 randomized multicenter 59 ThermoDox ® clinical 59 RE LY 59 ongoing Phase 1b 59 HDL Selective Delipidation 59 PORxin TM platforms 59 phase IIa clinical 59 Placebo Controlled 59 Initiates Phase 2b 59 Confirmatory Phase 59 systemic Phase 1b 59 BRIM2 59 toenail onychomycosis 59 dependent kinase inhibitor 59 ICON7 58 MEND CABG II 58 Phase IIb Clinical Trial 58 Proc Am Soc 58 Contrave# 58 Phase IIIb 58 Acute Decompensated Heart Failure 58 MKC# 58 placebo controlled Phase III 58 Randomized Clinical Trial 58 Multiple Ascending Dose 58 Randomized Clinical Trials 58 Eur Respir J 58 Pre RELAX AHF 58 AZX# Phase 58 INSPIRE Trial Phase III 58 ADVANCE ILLUMINATE 58 RE LY ® 58 phase IIb 58 Phase IIIb clinical 58 LymphoStat B belimumab 58 BR.# 58 Phase III placebo controlled 58 multicenter multinational 58 phase Ib clinical 58 ARCALYST ® rilonacept 58 multicenter Phase 58 Presents Preclinical 58 relapsed refractory multiple myeloma 58 Elagolix 58 PCI ExTRACT TIMI 58 landmark ATHENA 58 Albuferon Phase 58 double blinded randomized 58 oral Janus kinase 58 Pyridorin TM 58 ENGAGE AF TIMI 58 BY GUILLERMO 58 sodium glucose cotransporter 58 AFREZZA TM 58 TransVax TM 58 J Natl Cancer Inst 58 Renal Cell Carcinoma RCC 58 e# DOI #.#/journal.pone.# 58 Multicenter 58 TransVax ™ 58 Phase III Clinical Trial 58 Phase III randomized 58 Phase Ib Clinical Trial 58 Cites Positive 58 Dose Ranging Study 58 VEGFR2 inhibitor 58 ARDIS 58 Metastatic Melanoma 58 lorcaserin Phase 58 APEX PD 58 Demonstrates Positive 58 CALGB 58 mg BID dose 58 Sorafenib HCC Assessment 58 ID NCT# 58 Am J Epidemiol 58 prospective multicentre 58 Medullary Thyroid Cancer 58 MKC# MKC# PP 58 ENDEAVOR III 58 ONTARGET 58 daily Infergen 58 multicentre prospective 58 suppl S# S# 58 Pharmacokinetic parameters 58 multicenter prospective 58 Medidur TM FA 58 EDEMA3 57 CONQUER OB 57 plus Copegus R 57 Randomized Double Blind Placebo 57 phase IIb clinical 57 Matrix Phase 2b 57 J Am Acad 57 comparing alemtuzumab 57 Suppl. 57 ORACLE MS 57 hGH CTP Phase 57 Psychiatry Clin Neurosci 57 Trandolapril 57 azilsartan medoxomil 57 candidate CRLX# 57 Topics Covered I. INTRODUCTION 57 includes TOLAMBA TM 57 PANVAC VF 57 imetelstat GRN#L 57 J Am Coll 57 Phase 1a clinical 57 IMPACT DCM 57 TAXUS V 57 Ophena TM 57 Degarelix 57 Diabetic Foot Ulcer 57 Ozarelix 57 lintuzumab SGN 57 Severe Sepsis 57 ALN VSP Phase 57 Novel Oral 57 Phase #b/#a clinical 57 budesonide foam 57 TMC# C# 57 double blinded placebo 57 gastrin analogue TT 57 designated HVTN 57 Pivotal Trial 57 PFO migraine 57 bepotastine besilate nasal spray 57 blind randomized placebo 57 multicenter randomized placebo controlled 57 basal bolus regimen 57 UNCERTAINTY OF FUTURE FINANCIAL 57 alvespimycin 57 MERLIN TIMI 57 Acute Ischemic Stroke 57 SPIRIT FIRST 57 Protease Inhibitor 57 Arch Intern Med 57 trastuzumab DM1 T DM1 57 randomized Phase 2b 57 fosbretabulin 57 Glufosfamide 57 Ann Oncol 57 J Clin Endocrinol Metab 57 Phase 1b clinical trials 57 PARTNER Trial 57 unresectable stage 57 evaluable subjects 57 dosing cohorts 57 LUMINATE 57 midstage clinical 57 APPRAISE 57 Prolongs Survival 57 Refractory Angina 57 CLARITY TIMI 57 Postdoctoral Position 57 placebo controlled dose escalation 57 pharmacokinetic PK study 57 Bioavailability 57 PRECiSE 57 Placebo controlled 57 CYT# potent vascular disrupting 57 RADIANT 57 TKB# 57 CURRENT OASIS 7 57 blind multicenter 57 Zemplar Capsules 57 Kidney Int 57 prospective randomized placebo 57 AEGR 57 Orthop Surg 57 Vascular Disrupting Agent 57 EXECUTIVE SUMMARY 57 Hypoactive Sexual Desire Disorder 57 ACTEMRA TM 57 Obes Res 57 Entereg TM 57 davunetide intranasal AL 57 ORAL Solo 57 CAMMS# 57 MoneyTV Week 57 GVAX R 57 J Virol 57 Parathyroid Hormone 57 Pivotal Phase II 57 Clinical Trial Evaluating 57 Mg Usa 57 PSMA ADC 57 prospective multicenter randomized 57 ZYBRESTAT TM 57 Competitive Scenario 57 REG1 Anticoagulation System 57 oral ridaforolimus 57 Phase 2a clinical 57 First Patient Dosed 57 By KBJR News 57 phase IIa 57 Eluting Stent 57 Intervention Effectiveness CATIE 57 Voter Abstentions 56 Prostate Cancer Prevention 56 Acute Myocardial Infarction 56 GATTEX ® 56 TAXUS VI 56 Genasense oblimersen sodium Injection 56 R# #mg BID 56 REYATAZ r 56 Sapacitabine 56 Anti CD# Antibody 56 Janus kinase 56 Veronate R 56 ADMIRE HF 56 FASEB J. 56 Achieves Primary Endpoint 56 XL# SAR# 56 GetGoal Phase III 56 nucleotide analog 56 PC DAC Exendin 56 AVN# Phase 56 label multicenter Phase 56 Demonstrates Sustained 56 evaluating Actimmune 56 Risk Factors Item 56 worsening thrombocytopenia 56 e# [005] 56 APF# Phase 56 GW MILLER 56 TEMSO 56 Cancer Incidence Mortality 56 drug pipeline TAFA# 56 Dose Escalation 56 LymphoStat B Phase 56 Relapsing Multiple Sclerosis 56 EGFR HER2 56 Phase Ia 56 somatostatin analog 56 ROCKET AF 56 multicenter placebo controlled 56 retinal vein occlusion induced 56 dose escalation trial 56 Free Full Text 56 CATIE AD 56 satraplatin Phase 56 Prospective Multicenter 56 Phase #/#a 56 panose 1 56 First Patient Treated 56 #-# Full Text 56 BCIRG 56 Blind Placebo Controlled Trial 56 PREZISTA r arm 56 dose escalation Phase 56 Phase 2b Study 56 COU AA 56 including eniluracil ADH 56 Selective Electrochemical Tumor Ablation 56 Truvada tablets 56 Phase III Trial 56 includes investigational compounds 56 Phase III Clinical Trials 56 Brentuximab Vedotin SGN 56 Oral NKTR 56 Ann Rheum Dis 56 oral deforolimus 56 Multicentre 56 Double Blind Placebo 56 phase IIb study 56 Phase IIB 56 Phase 1a 56 Vaccine Adjuvant 56 Presents Preclinical Data 56 Decompensated Heart Failure 56 TRANSFORMS 56 phase IIb III 56 Pharmacodynamic 56 non nucleoside inhibitor 56 Angiographic 56 MAGE A3 ASCI 56 Advanced Melanoma 56 PROTECT AF 56 Child Adolesc Psychiatry 56 MSI #F 56 Anturol TM 56 Environ Health Perspect 56 PRIMO CABG 56 J Allergy Clin 56 RE MODEL 56 antibody MAb 56 Int Clin Psychopharmacol 56 Tezampanel 56 Ceflatonin R 56 Raloxifene Evaluation MORE 56 Placebo Controlled Trial 56 AAG geldanamycin analog 56 PHX# 56 ANCHOR trial 56 REG2 56 Telik logo TELINTRA 56 Advaxis Phase 56 Maven Semantic 56 ANN INTERN MED 56 GLOBAL MARKET PERSPECTIVE 56 EVEREST II 56 recurrent metastatic ovarian cancer 56 Xeloda ® 56 multicenter randomized clinical 56 TO AVOID PREGNANCY WHILE 56 randomized Phase III 56 Hormone Refractory Prostate Cancer 56 Edge STudy 56 hyperphenylalaninemia HPA due 56 JAK Inhibitor 56 DermaVir Patch 56 virus HCV protease inhibitor 56 myocardial infarction ventricular fibrillation 56 TAXUS IV 56 Phase 1b Clinical Trial 56 Vicriviroc 56 Content Outline 56 kidney urologic 56 label multicenter 56 Phase 1b clinical 56 label dose escalation 56 CRMD# 56 forodesine 56 J Acquir Immune Defic 56 comparing XIENCE V 56 programs visit http:/www.bionovo.com 55 Dermatol 55 BY ADRIAN NEMES 55 PERSEUS 55 Phase 2b RESTORE CLI 55 SinuNase ™ 55 XL# XL# XL# 55 J Rheumatol 55 Files IND 55 bapineuzumab AAB 55 Phase 2b monotherapy 55 Randomized Study 55 Antitumor Activity 55 Am J Obstet 55 evaluating Vectibix 55 pharmacokinetic PK 55 Cardiac Allograft Rejection 55 Obstet Gynecol 55 TRITON TIMI 55 Phase IIb Trial 55 POLITICS IN BRIEF 55 mGluR5 negative 55 Telik Announces 55 Morning Communiqué 55 SFinley San Francisco 55 By LEO SHANE 55 XPEL Announces 55 Bezielle 55 p# biomarker 55 Ambulatory Blood Pressure 55 controlled dose escalation 55 SPIRIT IV 55 ALISTA TM 55 Fast Tracked Phase 55 II Clinical Trial 55 ECASS 55 Ovarian PLCO Cancer 55 Phase III psoriasis 55 #G #M fly 55 Psychopharmacol 55 #:#-#,# CrossRef Medline [002] 55 successfully commercialize Iluvien 55 refractory gout 55 CIMZIA ™ 55 Efficacy Results 55 trastuzumab emtansine T DM1 55 unfractionated heparin UFH 55 By Nate Delesline 55 RG# ITMN 55 Nasdaq PGNX today 55 QLT Plug Delivery 55 PDX pralatrexate 55 controlled multicenter 55 evaluating REVLIMID 55 BARI 2D 55 Cardiol 55 oral picoplatin 55 Scandinavian Simvastatin Survival 55 plus dexamethasone 55 sorafenib tablets 55 Cancer Res 55 BiTE R 55 Therapeutic Competitors companiesandmarkets.com adEgemonye 55 Multicenter Randomized Double 55 blind randomized multicenter 55 Reports Preclinical Data 55 FOLFOX6 chemotherapy regimen 55 Teriflunomide 55 Phase IIb randomized 55 Blind Placebo Controlled 55 Evidence Therapeutic Level 55 J Pediatr 55 SANTE 55 telomerase therapeutic 55 Systemic Lupus Erythematosus SLE 55 SUCCEED trial 55 lexidronam injection 55 See CLINICAL PHARMACOLOGY 55 PROVENGE ® 55 Adjunctive Therapy 55 orally administered inhibitor 55 S1 S# [002] 55 sunitinib malate 55 Serious adverse reactions 55 Diabetic Nephropathy 55 galiximab 55 PEG INTRON R 55 refractory chronic lymphocytic 55 viral kinetics 55 avanafil PDE5 inhibitor 55 blind randomized controlled 55 intravenous methylnaltrexone 55 R#/MEM # 55 vesicular monoamine transporter 55 mGluR5 NAM 55 R lenalidomide 55 mg kg BID 55 CAPACITY trials 55 AVADO 55 Phase Ib study 55 trastuzumab Herceptin R 55 elotuzumab 55 Controlled Study 55 Antigen Specific 55 Randomized Controlled Trials 55 bazedoxifene conjugated estrogens 55 pain palliation 55 CLORETAZINE TM VNP#M 55 hyaluronidase enzyme 55 Phase 1b trial 55 Int J Radiat Oncol 55 prospective randomized multicenter 55 Active Ulcerative Colitis 55 Unstable Angina 55 CTA# Injection 55 randomized Phase IIb 55 By PAYTON TOWNS 55 placebo controlled clinical 55 NCT# ClinicalTrials.gov 55 By JAMES JOYCE 55 Meta Analysis 55 relapsing multiple sclerosis 55 ATTAIN 55 immunosuppressive compound 55 dose escalation phase 55 Clostridium difficile Infection 55 MVA MUC1 IL2 55 By Arek Sarkissian 55 #rd Annual CTRC 55 relapsing remitting MS RRMS 55 generation URAT1 inhibitor 55 HCV NS5B polymerase 55 inhibitor RG# 55 methionine aminopeptidase 55 Randomized Trials 55 ara C 55 Wisconsin Sleep Cohort 55 RESTORE CLI trial 55 prospective observational cohort 55 riociguat 55 #.#/journal.pmed.# 55 Receives Orphan Drug Designation 55 Qutenza TM 55 randomized Phase 55 stated Michelle Berrey 55 PEGINTRON TM 55 prospective observational 55 cytokine refractory 55 Polymerase Inhibitor 55 Personalized Immunotherapy 55 Silodosin 55 HPV-#/# 55 http:/www.vivus.com 55 Cloretazine ® 55 Cholesterol Levels SPARCL 55 Long Lesion 55 viral kinetic 54 Primary endpoints 54 NATRECOR R 54 Screening Trial 54 Pharmacokinetic Study 54 Androxal TM 54 randomized multicenter Phase III 54 Arch Surg 54 subcutaneous PRO 54 Ann Intern Med 54 IL# PE#QQR 54 J Biol Chem 54 STAR WARS ARCHIVES EPISODES 54 sodium thiosulfate STS 54 mg administered orally 54 certolizumab 54 mean ± SEM 54 HGS ETR2 54 AVOREN 54 J Immunol 54 q8h 54 interferon gamma 1b 54 ADVANCE PD 54 Rapeseed Rajasthan #/#.# # 54 Solorel TM 54 Clinical Outcome 54 STRATEGY FOR AN OPEN 54 CD# [004] 54 International Verapamil SR 54 null responder HCV 54 Solazed TM 54 PEG IFN 54 J Nerv Ment Dis 54 Breast Carcinoma 54 #nd EORTC NCI 54 BY FRANK RADOSEVICH 54 Safinamide 54 Prodarsan R 54 Subgroup Analysis 54 acyclovir Lauriad ® 54 FAME Study 54 EINSTEIN DVT 54 Pharmacokinetic 54 Entereg R 54 Hedgehog Pathway Inhibitor 54 #:#-# [020] 54 TRA 2P 54 antiretroviral naïve 54 relapsed myeloma 54 recurrent glioblastoma multiforme 54 DRoberts San Diego 54 Rigel R# 54 BY LAWRENCE LATANE 54 LAB CGRP 54 liposomal formulation 54 CONSERV 54 non nucleoside HCV 54 Preclinical Study 54 TRACON Pharmaceuticals Inc. 54 Nuvelo Announces 54 www.ClinicalTrials.gov 54 Phase IIIB IV 54 oral FTY# 54 μg dose 54 please visit www.brighamandwomens.org 54 LibiGel Phase III 54 GAMMAGARD 54 adverse reactions ≥ 54 MADIT II 54 acyclovir Lauriad R 54 suppl. 54 Outpatient Setting 54 juli kl #.# 54 pharmacokinetics PK 54 randomized controlled clinical 54 multicenter randomized 54 MGd 54 confirmatory clinical 54 CLL8 54 Marvin Hurst KENS 54 ENDEAVOR IV clinical 54 AERAS-#/Crucell Ad# 54 Folfox 54 Systemic Delivery 54 randomized multicenter trial 54 PET FROM 54 initiate Phase 1b 54 pharmacodynamic PK PD 54 #-#.#.# [001] 54 #:#-# [007] 54 VICTOR E1 54 PERSEUS clinical program 54 Initiate Phase II 54 Cholinesterase Inhibitors 54 Platelet Inhibition 54 Prevalence Worldwide 54 VFEND 54 XIENCE V demonstrated 54 placebo controlled randomized 54 mertansine 54 AEG# 54 pivotal bioequivalence 54 huN# DM1 54 #G #M breast 54 Nasdaq IDRA today 54 Aflibercept 54 ToGA 54 retrospective cohort 54 GABITRIL 54 REMINYL ® 54 Abstract Accepted 54 taxane resistant 54 PLEASE READ THE FOLLOWING 54 Plaque Psoriasis 54 Intervention Trial GAIT 54 Phase 2a Clinical Trial 54 TELINTRA R 54 prasterone 54 Granted Orphan Drug 54 diarrhea predominant irritable 54 pharmacodynamic profiles 54 intravesical infusion therapy 54 BY RICH MCCRACKEN 54 YONDELIS 54 BENICAR HCT 54 ART THOMPSON 54 DIRECT Trial 54 papillary renal cell carcinoma 54 ABSORB trial 54 BioSante Pharmaceuticals Reports 54 alfa 2a 54 J Nutr 54 Tyrosine Kinase Inhibitor 54 CIMZIA TM certolizumab pegol 54 iniparib BSI 54 Long Term Efficacy 54 Trastuzumab DM1 54 TBC# 54 evaluating Prochymal 54 TLK# 54 heFH 54 Hematological 54 biliary tract cancer 54 masked placebo controlled 54 Phase IIa clinical 54 cisplatin gemcitabine 54 Syncria albiglutide 54 Ecallantide 54 J Am Soc 54 Arch Otolaryngol Head 54 Daclizumab 54 randomized discontinuation trial 54 BY ART THOMPSON 54 Phase 1b dose escalation 54 Quinamed 54 ARB telmisartan 54 Investigational Drug 54 Antiviral Therapy 54 dose cohort 54 Infusion Reactions Severe 54 Receives Orphan Drug 54 Systematic Review 54 ancrod 54 Xelox 54 BLOOM Behavioral modification 54 NABTT 54 abstr 54 NSABP C 54 R roscovitine CDK cyclin 54 velafermin 54 pgs #k 54 suppl #S 54 Aplidin R 54 Enzastaurin 54 label multicenter randomized 54 Noncritical violations found 54 OPT CHF 54 Abstract Full Text 54 selective phosphodiesterase 54 recurrent glioma 54 Dry Powder Inhalers 54 telaprevir dosed 54 #mg dose [002] 54 colesevelam HCl 54 Amrubicin 54 Clolar ® 54 observational cohort study 53 Xcytrin R 53 Cleator MC 53 metastatic GIST 53 Phase III Psoriasis 53 PI3K/Akt pathway inhibitor 53 Non inferiority 53 Shows Promise Against 53 Current Controlled Trials 53 phase IIb trial 53 Antiviral Activity 53 beta 1a 53 By Linwood Outlaw 53 Recurrent Glioblastoma 53 ZACTIMA 53 albiglutide 53 SinuNase TM 53 brivanib 53 Psychopharmacol Bull 53 Patients Treated With 53 PROMUS Element Stent 53 DAPT Study 53 registrational trial 53 AKT inhibitor 53 EDEMA3 trial 53 ALN HPN 53 Hematological Cancers 53 recurrent malignant glioma 53 Echocardiographic 53 Brussels GLPG 53 evaluating carfilzomib 53 Pharmacokinetic PK 53 ZYBRESTAT 53 ABL inhibitor 53 Pivotal Study 53 SPIRIT III 53 Stocks Approaching Greatness 53 NCCTG 53 conducted retrospective cohort 53 Kahalalide F 53 Prostate Lung Colorectal 53 NCI Cancer 53 Panzem NCD 53 Inc. Nasdaq ALSE 53 Linagliptin 53 EDEMA4 53 simplex virus 53 Infarct 53 Demonstrates Significant 53 ALISTA 53 CG# oncolytic virus 53 Tesmilifene 53 Dose Response 53 SOCIAL IN BRIEF 53 SHIFT FOCUS EPISODE 53 COSTAR II 53 TMC# r 53 COPERNICUS 53 Phase IIa Clinical Trial 53 Ranolazine 53 nitazoxanide 53 velafermin belinostat 53 TMC# [002] 53 Adjuvant Treatment 53 Initiate Clinical Trial 53 CRLX# 53 Virulizin ® 53 polyunsat 53 CR# vcMMAE 53 oral rivaroxaban 53 HCD# [002] 53 Edwin M. Fayia 53 Prospective Randomized Trial 53 adecatumumab 53 ACCEDE 53 Preclinical Data 53 Pharmacokinetics PK 53 visilizumab 53 SPRYCEL ® 53 Stenting Trial CREST 53 DASISION 53 Novel Therapeutic 53 vapreotide acetate 53 selectin antagonist 53 Phase 2a trial 53 EchoCRT 53 Abstract Free Full Text 53 Acetavance TM intravenous acetaminophen 53 Cetrorelix 53 Nephrol 53 tramiprosate Alzhemed TM 53 Pegasys peginterferon alfa 2a 53 YOUR LOCAL ANIMAL SHELTER 53 Vitro Activity 53 Offsides h 53 Stent Implantation 53 PREZISTA ritonavir 53 Triapine R 53 Allovectin 7 R 53 ORAL Sync 53 preclinical efficacy 53 REALITY Trial 53 Genasense ® oblimersen 53 Biopharmaceuticals AG 53 Pharmacogenomic 53 cobiprostone 53 icatibant 53 doi #.#/fj.#-# 53 EXPAREL TM 53 Diabetic Neuropathy 53 Provides Detailed 53 metaglidasen 53 BOLDER II 53 ONGLYZA saxagliptin 53 Deutsche Welle Newslink 53 mGluR2 positive 53 Intervention Trial 53 compound INCB# 53 SPL# Gel vaginal microbicide 53 JVRS 53 GENASIS clinical 53 dextromethorphan quinidine 53 fostamatinib 53 dose cohorts 53 maximally tolerated dose 53 CrossRef Medline 53 omacetaxine mepesuccinate 53 rALLy trial 53 Xanafide 53 Kinase Inhibitor 53 Pralatrexate 53 MIST II 53 prospective multicenter 53 investigational protease inhibitor 53 AND SCIENCE 53 Multicenter Study 53 Immunogenicity 53 Percutaneous Tibial Nerve Stimulation 53 stage IIIB 53 Late Breaker 53 Thrombolysis 53 pimecrolimus cream 53 Sw = 53 ILLUMINATE 53 telomerase inhibitor drug 53 CAPITAL ACCOUNT 53 Phase IIb trials 53 www.vivus.com 53 EQUIP OB 53 #:#-#,# [002] 53 Phase 2a clinical trials 53 Tarceva TM 53 hoFH 53 ritonavir boosted 53 NATRECOR ® 53 ongoing Phase IIIb 53 Phase III VISTA 53 La Mina Porphyry 53 Arch Pediatr Adolesc Med 53 GBP JPY Classical 53 blinded placebo controlled 53 Afatinib 53 Prognostic Value 53 QD dosing